Skip to content
Company Analysis

GeneDx Holdings Corp. WGSWW

A comprehensive view of key metrics, scores, and financial health for GeneDx Holdings Corp.

Overview of GeneDx Holdings Corp.

WGSWW NMS
Healthcare Diagnostics & Research Framework: Medical Devices & Diagnostics
GeneDx Holdings Corp. (WGSWW), in the Diagnostics & Research industry, last closed at $0.01, about 0.0% overvalued vs fair value, ranked 633/1122 in sector.
USD 0.01
-28.21%
(Delayed)
• Vol 90d: 263.8%
52-Week Range
Enterprise Value
-
Overall Score
View breakdown
Overall
Growth
Good
Profitability
Fair
Health
Fair
Efficiency
Fair
Growth
Good
Profitability
Fair
Health
Fair
Efficiency
Fair
Completeness: 56%
Confidence: 38%
Updated: Mar 8
Top Beats

Quick Facts

Website https://www.genedx.com
HQ Stamford, CT
Employees 1,300
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Insufficient data
Show more details
  • Shares outstanding missing or non-positive

Engine Room Money Flow™

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$305.4M
50.8%%
Gross Profit
$194.4M
116%%
Operating Income (GAAP)
$-23.2M
86.4%%
EBITDA
$-1.3M
99.1%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
63.6%
Good

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
1
Active Leaks
0/1
Improving
0
High Impact
1
Critical
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating GeneDx Holdings Corp.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
51
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Developing
44
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 81% Coverage
Trade-Off Triangle Visualization A ternary plot showing WGSWW's balance between Growth (44.2%), Profitability (30.9%), and Safety (24.9%). Growth 44% Safety 25% Profitability 31%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

78th percentile vs peers
79
Key Signals
Rev Growth YoY 50.8% 89p Revenue CAGR 3Y 12.9% 65p
Strengths
  • Rev Growth YoY in top 20% of peers (50.8%, 89th percentile)
  • Strong liquidity position vs peers
  • Conservative leverage compared to industry peers
Risks

No significant risks identified for this axis.

Profitability

54th percentile vs peers
55
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

44th percentile vs peers
44
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for GeneDx Holdings Corp..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
-
- - -
- upside
-
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000